Acorda announces data of GGF2 preclinical research for focal ischemic stroke Acorda Therapeutics.

The business can be pursuing preclinical research in additional cardiac and neurological applications for GGF2 and various other neuregulin growth factors. Related StoriesMD Anderson study reveals why chemotherapy medications not effective for many pancreatic cancer patientsMeat-rich diet plan may increase kidney tumor riskStudy shows rare HER2 missense mutations usually do not spread breasts cancer on the ownAlthough putting polymer implants directly at the site of tumor can be a successful treatment for cancers of the mind, Saltzman says that success of this approach is minimized because in most cases the drug does not penetrate in to the brain far more than enough for optimum treatment and there is quick clearance of the medication from the site.We measure a lot of things that have no value to patients, while a lot of what individuals do value, including our attention, remains unmeasurable. Why, Wachter asks, do we do nothing identical in health care? In a moving passage, Wachter speaks with a famous surgeon who once spent his evenings before surgery reading his notes on another day’s patients. No longer. His notes have been rendered homogeneous by the tyranny of clicks and auto-populated fields uselessly.